The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. For Pfizer, this acquisition represents a strategic pivot into the obesity market, leveraging the company's extensive cardiometabolic experience and global manufacturing capabilities to accelerate development of what CEO Albert Bourla described as "potential best-in-class injectables" with differentiated efficacy, tolerability, and monthly dosing convenience.